Elevated resting [Ca2+]i in myotubes expressing malignant hyperthermia RyR1 cDNAs is partially restored by modulation of passive calcium leak from the SR

American Journal of Physiology - Cell Physiology

Volumn 292, Issue 5, 2007, Pages

  Yang, Tianzhong ^a   Esteve, Eric ^a   Pessah, Isaac N ^b   Molinski, Tadeusz F ^c   Allen, Paul D ^a   López, José R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bastadin 5; FLA 365; Resting intracellular calcium concentration; Ryanodine; Sarcoplasmic reticulum

Indexed keywords

2,6 DICHLORO 4 DIMETHYLAMINOAMPHETAMINE; BASTADIN 5; CALCIUM; COMPLEMENTARY DNA; PROPYLAMINE; RYANODINE; RYANODINE RECEPTOR 1; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; DIPHENYL ETHER DERIVATIVE; PHENETHYLAMINE DERIVATIVE; RYANODINE RECEPTOR;

ARTICLE; CALCIUM CELL LEVEL; GENE EXPRESSION; GENE MUTATION; MALIGNANT HYPERTHERMIA; MICROELECTRODE; MISSENSE MUTATION; MUSCLE FIBRIL; MYOTUBE; PRIORITY JOURNAL; PROTEIN CONFORMATION; SARCOPLASMIC RETICULUM; ALLOSTERISM; ANIMAL; CELL LINE; CHEMISTRY; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; HUMAN; ION SELECTIVE ELECTRODE; METABOLISM; MUSCLE CELL; MUTATION;

ALLOSTERIC REGULATION; ANIMALS; CALCIUM; CELL LINE; DNA, COMPLEMENTARY; HUMANS; ION-SELECTIVE ELECTRODES; MALIGNANT HYPERTHERMIA; MICROELECTRODES; MUSCLE FIBERS; MUTATION; PHENETHYLAMINES; PHENYL ETHERS; PROTEIN CONFORMATION; RYANODINE; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM; TRANSFECTION;

EID: 34250656580     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00133.2006     Document Type: Article

References (55)

1. Anetseder M, Hager M, Muller-Reible C, Roewer N. Regional lactate and carbon dioxide concentrations in a metabolic test for malignant hyperthermia. Lancet 362: 494-495, 2003.
2. Avila G, Dirksen RT. Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor. J Gen Physiol 118: 277-290, 2001.
3. 2+] in developing rat myotubes at rest and in response to stimulation. Cell Calcium 19: 409-418, 1996.
4. 31Phosphorus magnetic resonance spectroscopy characterization of muscular metabolic anomalies in patients with malignant hyperthermia: application to diagnosis. Anesthesiology 88: 96-107, 1998.
5. + channels in excitable cells. Prostaglandins Other Lipid Mediat 77: 103-110, 2005.
6. Beutner G, Sharma VK, Lin L, Ryu SY, Dirksen RT, Sheu SS. Type 1 ryanodine receptor in cardiac mitochondria: transducer of excitation-metabolism coupling. Biochim Biophys Acta 1717: 1-10, 2005.
7. Bina S, Cowan G, Karaian J, Muldoon S, Mongan P, Bunger R. Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis. Anesthesiology 104: 90-100, 2006.
8. Buck E, Zimanyi I, Abramson JJ, Pessah IN. Ryanodine stabilizes multiple conformational states of the skeletal muscle calcium release channel. J Biol Chem 267: 23560-23567, 1992.
9. Calviello G, Chiesi M. Rapid kinetic analysis of the calcium-release channels of skeletal muscle sarcoplasmic reticulum: the effect of inhibitors. Biochemistry 28: 1301-1306, 1989.
10. 2+ release regulation in junctional sarcoplasmic reticulum. Arch Biochem Biophys 290: 239-247, 1991.
11. Chiesi M, Schwaller R, Calviello G. Inhibition of rapid Ca-release from isolated skeletal and cardiac sarcoplasmic reticulum (SR) membranes. Biochem Biophys Res Commun 154: 1-8, 1988.
12. 2+ handling caused by malignant hyperthermia and central core disease mutations in RyR1. Biophys J 87: 3193-3204, 2004.
13. Ducreux S, Zorzato F, Muller C, Sewry C, Muntoni F, Quinlivan R, Restagno G, Girard T, Treves S. Effect of ryanodine receptor mutations on interleukin-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia-susceptible individuals and patients affected by central core disease. J Biol Chem 279: 43838-43846, 2004.
14. Iaizzo PA, Klein W, Lehmann-Horn F. Fura-2 detected myoplasmic calcium and its correlation with contracture force in skeletal muscle from normal and malignant hyperthermia susceptible pigs. Pflügers Arch 411: 648-653, 1988.
15. 2+] in human skeletal muscle. Cell Calcium 10: 151-158, 1989.
16. + and tetracaine in cultured rat myotubes. Cell Calcium 15: 356-368, 1994.
17. + channels TREK-2 and TRAAK. J Physiol 564: 103-116, 2005.
18. 3 muscarinic receptor. Am J Physiol Cell Physiol 291: C649-C656, 2006.
19. + channels in dorsal root ganglion neurons. Am J Physiol Cell Physiol 291: C138-C146, 2006.
20. Kim D. Physiology and pharmacology of two-pore domain potassium channels. Curr Pharm Design 11: 2717-2736, 2005.
21. Lee EH, Lopez JR, Li J, Protasi F, Pessah IN, Kim DH, Allen PD. Conformational coupling of DHPR and RyR1 in skeletal myotubes is influenced by long-range allosterism: evidence for a negative regulatory module. Am J Physiol Cell Physiol 286: C179-C189, 2004.
22. Lentz M, Nielsen JF. Post-exercise facilitation and depression of M wave and motor evoked potentials in healthy subjects. Clin Neurophysiol 113: 1092-1098, 2002.
23. Lopez JR, Alamo L, Caputo C, DiPolo R, Vergara S. Determination of ionic calcium in frog skeletal muscle fibers. Biophys J 43: 1-4, 1983.
24. Lopez JR, Alamo L, Caputo C, Wikinski J, Ledezma D. Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia. Muscle Nerve 8: 355-358, 1985.
25. 2+ selective microelectrodes. Muscle Nerve 9: 85-86, 1986.
26. Lopez JR, Allen P, Alamo L, Ryan JF, Jones DE, Sreter F. Dantrolene prevents the malignant hyperthermic syndrome by reducing free intracellular calcium concentration in skeletal muscle of susceptible swine. Cell Calcium 8: 385-396, 1987.
27. 2+] during a malignant hyperthermia episode in swine. Muscle Nerve 11: 82-88, 1988.
28. 2+]. Anesthesiology 92: 1799-1806, 2000.
29. 2+] measured in vivo in patients susceptible to malignant hyperthermia. Anesthesiology 76: 711-719, 1992.
30. Mack MM, Molinski TF, Buck ED, Pessah IN. Novel modulators of skeletal muscle FKBP12/calcium channel complex from Ianthella basta. Role of FKBP12 in channel gating. J Biol Chem 269: 23236-23249, 1994.
31. 2+ release channel of sarcoplasmic reticulum. J Biol Chem 261: 6300-6306, 1986.
32. Merickel M, Gray R, Chauvin P, Appel S. Electrophysiology of human muscle in culture. Exp Neurol 72: 281-293, 1981.
33. 2+ regulation defects. Physiol Rev 76: 537-592, 1996.
34. 31P-MR spectroscopy. J Neurol 244: 651-656, 1997.
35. Moore RA, Nguyen H, Galceran J, Pessah IN, Allen PD. A transgenic myogenic cell line lacking ryanodine receptor protein for homologous expression studies: reconstitution of Ry1R protein and function. J Cell Biol 140: 843-851, 1998.
36. ++ regulating proteins. Curr Mol Med 2: 347-369, 2002.
37. Olgin J, Argov Z, Rosenberg H, Tuchler M, Chance B. Non-invasive evaluation of malignant hyperthermia susceptibility with phosphorus nuclear magnetic resonance spectroscopy. Anesthesiology 68: 507-513, 1988.
38. Olgin J, Rosenberg H, Allen G, Seestedt R, Chance B. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility. Anesth Analg 72: 36-47, 1991.
39. Payen JF, Bosson JL, Bourdon L, Jacquot C, Le Bas JF, Stieglitz P, Benabid AL. Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy. Anesthesiology 78: 848-855, 1993.
40. 2+ efflux pathways in skeletal SR and BC3H1 cells. Am J Physiol Cell Physiol 272: C601-C614, 1997.
41. 2+ release channel of sarcoplasmic reticulum from skeletal and cardiac muscle: evidence for a sequential mechanism in ryanodine action. Mol Pharmacol 39: 679-689, 1991.
42. 2+ release channel. Am J Physiol Cell Physiol 253: C364-C368, 1987.
43. + channels into open leak channels. EMBO J 25: 5864-5872, 2006.
44. + ionophores in L6 myotubes. Proc Natl Acad Sci USA 73: 1355-1359, 1976.
45. Schuster F, Scholl H, Hager M, Muller R, Roewer N, Anetseder M. The dose-response relationship and regional distribution of lactate after intramuscular injection of halothane and caffeine in malignant hyperthermia-susceptible pigs. Anesth Analg 102: 468-472, 2006.
46. 2+-leak channel: cell biological and pathological consequences. Biol Cell 98: 1-14, 2006.
47. Takahashi A, Camacho P, Lechleiter JD, Herman B. Measurement of intracellular calcium. Physiol Rev 79: 1089-1125, 1999.
48. 2+ release channels. J Biol Chem 274: 693-702, 1999.
49. Wang Y, Fraefel C, Protasi F, Moore RA, Fessenden JD, Pessah IN, DiFrancesco A, Breakefield X, Allen PD. HSV-1 amplicon vectors are a highly efficient gene delivery system for skeletal muscle myoblasts and myotubes. Am J Physiol Cell Physiol 278: C619-C626, 2000.
50. 2+ release event activity in both intact and permeabilized myotubes. Biophys J 81: 3216-3230, 2001.
51. Wehner M, Rueffert H, Koenig F, Neuhaus J, Olthoff D. Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation. Clin Genet 62: 135-146, 2002.
52. Weiss RG, O'Connell KM, Flucher BE, Allen PD, Grabner M, Dirksen RT. Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. Am J Physiol Cell Physiol 287: C1094-C1102, 2004.
53. Yang T, Ta TA, Pessah IN, Allen PD. Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling. J Biol Chem 278: 25722-25730, 2003.
54. 2+ sparks demonstrated in cultured mammalian muscle. Am J Physiol Cell Physiol 290: C539-C553, 2006.
55. 2+ release channel from skeletal muscle sarcoplasmic reticulum. Mol Pharmacol 42: 1049-1057, 1992.